Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Rescission package vote casts shadow over health care initiatives
WASHINGTON — Congressional Republicans early on Friday morning passed legislation to take back money they had already appropriated…
GSK’s blood cancer drug Blenrep hits setback with FDA advisers
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
We’re reading about GLP-1 drugs for addiction, FDA funding
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,…
Hospitals brace for Medicaid cuts, Humana’s latest Medicare doctor bet
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Medicaid fight puts partisan mistrust at heart of health care policy issues
WASHINGTON — Republicans’ first major policy bill this year was a partisan affair: They cut Medicaid funding by…
FDA focuses attention on rejected drug decisions
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…